DE17829597T1 - Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz - Google Patents

Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz Download PDF

Info

Publication number
DE17829597T1
DE17829597T1 DE17829597.8T DE17829597T DE17829597T1 DE 17829597 T1 DE17829597 T1 DE 17829597T1 DE 17829597 T DE17829597 T DE 17829597T DE 17829597 T1 DE17829597 T1 DE 17829597T1
Authority
DE
Germany
Prior art keywords
nucleic acid
amino
reactant
acid molecule
modified nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE17829597.8T
Other languages
German (de)
English (en)
Inventor
Lucas Bethge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TME Pharma AG
Original Assignee
Noxxon Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of DE17829597T1 publication Critical patent/DE17829597T1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE17829597.8T 2016-11-30 Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz Pending DE17829597T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16201391 2016-11-30
EP16201391 2016-11-30
EP17829597.8A EP3548089B1 (fr) 2016-11-30 2017-11-30 Procédé de polyalcoxylation d'acides nucléiques permettant la récupération et la réutilisation d'un réactif de polyalcoxylation en excès
PCT/EP2017/001399 WO2018099600A1 (fr) 2016-11-30 2017-11-30 Procédé de polyalcoxylation d'acides nucléiques permettant la récupération et la réutilisation d'un réactif de polyalcoxylation en excès

Publications (1)

Publication Number Publication Date
DE17829597T1 true DE17829597T1 (de) 2019-12-05

Family

ID=57544196

Family Applications (1)

Application Number Title Priority Date Filing Date
DE17829597.8T Pending DE17829597T1 (de) 2016-11-30 Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz

Country Status (12)

Country Link
US (1) US11459352B2 (fr)
EP (1) EP3548089B1 (fr)
JP (1) JP7113825B2 (fr)
KR (1) KR102611562B1 (fr)
CN (1) CN110121363B (fr)
BR (1) BR112019009373A8 (fr)
CA (1) CA3043478C (fr)
DE (1) DE17829597T1 (fr)
MX (1) MX2019006363A (fr)
RU (1) RU2765027C2 (fr)
SG (1) SG10202105648XA (fr)
WO (1) WO2018099600A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263937B2 (en) 2002-08-19 2010-04-01 The President And Fellows Of Harvard College Evolving new molecular function
EP1620118B1 (fr) * 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Medicaments pegyles reversibles
US20050089952A1 (en) * 2003-10-22 2005-04-28 Akzo Nobel N.V. Apparatuses and processes for increasing protein PEGylation reaction yields
SG161311A1 (en) * 2005-05-04 2010-05-27 Noxxon Pharma Ag Novel use of spiegelmers
US9388457B2 (en) * 2007-09-14 2016-07-12 Affymetrix, Inc. Locus specific amplification using array probes
DE102007058713A1 (de) * 2007-12-06 2009-06-10 Evonik Goldschmidt Gmbh Silicon(meth-)acrylat-Partikel, Verfahren zu deren Herstellung sowie deren Verwendung
US8207298B2 (en) 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
TWI578992B (zh) 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
SG194626A1 (en) * 2011-04-26 2013-12-30 Regado Biosciences Inc A method for manufacturing pegylated oligonucleotides
US20150232852A1 (en) 2011-10-21 2015-08-20 Noxxon Pharma Ag Glucagon Binding Nucleic Acids
DK2825156T3 (en) * 2012-03-16 2017-10-30 Merck Patent Gmbh TARGETED AMINO ACID LIPIDS
EP3102243A1 (fr) 2014-02-03 2016-12-14 Noxxon Pharma AG Procedes de preparation d'une molecule d'acide nucleique polyalcoxylee

Also Published As

Publication number Publication date
AU2017369207A1 (en) 2019-05-23
AU2017369207A9 (en) 2019-07-25
EP3548089B1 (fr) 2023-12-27
BR112019009373A2 (fr) 2019-07-23
WO2018099600A1 (fr) 2018-06-07
RU2019120021A (ru) 2021-01-11
CN110121363B (zh) 2023-08-29
CA3043478A1 (fr) 2018-06-07
RU2019120021A3 (fr) 2021-04-06
MX2019006363A (es) 2019-11-12
EP3548089C0 (fr) 2023-12-27
CA3043478C (fr) 2023-07-25
US20200291057A1 (en) 2020-09-17
SG10202105648XA (en) 2021-06-29
EP3548089A1 (fr) 2019-10-09
RU2765027C2 (ru) 2022-01-24
JP2020500519A (ja) 2020-01-16
AU2017369207B2 (en) 2023-12-14
CN110121363A (zh) 2019-08-13
US11459352B2 (en) 2022-10-04
KR20190088062A (ko) 2019-07-25
BR112019009373A8 (pt) 2023-04-11
KR102611562B1 (ko) 2023-12-07
WO2018099600A8 (fr) 2019-07-04
WO2018099600A9 (fr) 2023-12-28
JP7113825B2 (ja) 2022-08-05

Similar Documents

Publication Publication Date Title
CN106397577B (zh) 双重刺激响应型胶原蛋白多肽聚合物及其制备方法
EP0931038B1 (fr) Nouvelle bibliotheque de substances et complexes supramoleculaires obtenus au moyen de ladite bibliotheque
EP2464669A2 (fr) Procédé pour modifier et fonctionnaliser des saccharides
DE17829597T1 (de) Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
DE2253327A1 (de) Verfahren zur herstellung von insulin, insulin-analogen und -derivaten
DE1643345C3 (de) Glucagonderivat und Verfahren zur Herstellung von Glucagon
DE2047413C3 (de) Verfahren zur Herstellung von Peptiden in homogener Phase
CN110627875A (zh) 一种线粒体靶向透膜环肽及其制备方法和用途
DE69834057T2 (de) Echinocandinderivate, deren herstellung und deren verwendung zur bekämpfung von pilzen
EP0700928A1 (fr) Oligomères qui se lient aux acides nucléiques pour la thérapie et le diagnostic
ITVI20130233A1 (it) Procedimento per la concia del pellame con derivati della triazina
DE60222189T2 (de) Zwischenprodukte für die Synthese von LHRH-Antagonisten, Verfahren zu deren Herstellung und Verfahren zur Herstellung von LHRH-Antagonisten
DE2455623C3 (de) Verfahren zur Herstellung von N-Acylaminocarbonsäurepoyläthylenglykolestern
EP0970113A1 (fr) Nouveaux elements constitutifs monomeres pour marquer les acides nucleiques peptidiques
EP1212351A1 (fr) Procede de production de peptidomimetiques cycliques
Roviello et al. Synthesis of a thymine-functionalized nucleoamino acid for the solid phase assembly of cationic nucleopeptides
Matera-Witkiewicz et al. Short-chain oligopeptides with copper (II) binding properties: The impact of specific structural modifications on the copper (II) coordination abilities
KR101692992B1 (ko) 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
DE02703115T1 (de) Verbessertes verfahren zur herstellung von reinem ondansetronhydrochlorid-dihydrat
JP2020500519A5 (fr)
EP3448864A1 (fr) Silsesquioxanes utilisés comme composés porteurs
KR101855531B1 (ko) 코어―쉘 구조의 아미노폴리스티렌 수지 및 이의 제조 방법
ALBINI Study of the cellulose-peptide conjugation for the development of antimicrobial cotton textiles
CN110669107B (zh) 抗菌肽及其制备方法
Neuhaus Asymmetrically branched sequence-controlled glycooligomers as sugar mimetic ligands for specific receptor targeting